Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAi

PUBLISHER: Acute Market Reports | PRODUCT CODE: 1347831

Cover Image

PUBLISHER: Acute Market Reports | PRODUCT CODE: 1347831

Cell and Gene Therapy Manufacturing Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031

PUBLISHED:
PAGES: 115 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 6500
PDF (Enterprise License)
USD 9000

Add to Cart

Description

Table of Contents

List of Tables

The cell and gene therapy manufacturing market is expected to grow at a CAGR of 17.3% during the forecast period of 2023 to 2031. The market has emerged as a groundbreaking sector within the biopharmaceutical industry, revolutionizing medical treatment through personalized therapies. The cell and gene therapy manufacturing market is driven by advancements in cellular engineering, rising disease prevalence, and a supportive regulatory environment. Complex manufacturing processes pose challenges that need to be addressed to ensure consistent product quality and reproducibility. Established players are poised to drive innovation and collaboration to bring transformative therapies to patients, ultimately reshaping the landscape of medical treatment and patient outcomes. As the market continues to evolve, cell and gene therapies are expected to play a pivotal role in addressing unmet medical needs and providing hope for patients with previously untreatable diseases.

Advancements in Cellular Engineering and Biotechnology

The cell and gene therapy manufacturing market is driven by remarkable advancements in cellular engineering and biotechnology. Scientists and researchers are leveraging cutting-edge techniques to modify and engineer cells, enabling them to target and treat specific diseases at the genetic level. Techniques such as CRISPR-Cas9 gene editing have paved the way for precise modifications, resulting in innovative therapies. These advancements have allowed the development of therapies that were once considered science fiction, leading to the emergence of treatments that address unmet medical needs, such as rare genetic disorders. The Journal of Clinical Investigation reports successful outcomes in clinical trials using CRISPR-based therapies, showcasing the potential of gene editing in disease treatment.

Rising Prevalence of Chronic and Genetic Diseases

The increasing prevalence of chronic and genetic diseases, particularly oncology diseases and genetic disorders, has fueled the demand for cell and gene therapies. Traditional treatment options for such diseases often provide limited efficacy, leading to the exploration of novel therapies. Cell and gene therapies offer the promise of targeted and personalized treatment approaches that address the root causes of these diseases. For instance, the American Cancer Society highlights that cancer remains a significant global health concern, and advancements in gene therapy are enabling the development of therapies that target specific cancer mutations, increasing treatment efficacy and reducing side effects.

Supportive Regulatory Environment

The evolving regulatory landscape and support from regulatory authorities have played a crucial role in driving the cell and gene therapy manufacturing market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have introduced expedited pathways for the approval of regenerative and gene therapies, recognizing the potential of these therapies to address unmet medical needs. These pathways facilitate faster development and approval of innovative therapies, fostering investment and collaboration in the field. The FDA's approval of various cell and gene therapies, including CAR-T cell therapies, illustrates the agency's commitment to advancing these treatments.

Complex Manufacturing Processes

A notable restraint in the cell and gene therapy manufacturing market is the complexity of manufacturing processes. Cell and gene therapies often involve intricate processes for isolating, modifying, and culturing cells, as well as ensuring their safe delivery to patients. Achieving consistent product quality, and scalability, and maintaining regulatory compliance pose challenges. Additionally, cell and gene therapies are highly individualized and require close coordination between healthcare providers, manufacturers, and regulatory bodies. Addressing these challenges to streamline manufacturing processes and ensure reproducibility is critical to advancing the field.

Oncology Diseases Segment Dominates the Market by Indication

The market is segmented by indication into Oncology Diseases, Cardiovascular Diseases, Orthopedic Diseases, Ophthalmology Diseases, Central Nervous System Disorders, Infectious Diseases, and Other Indications. In 2022, the Oncology Diseases segment recorded the highest revenue due to the significant research and development efforts focused on cancer therapies. During the forecast period of 2023 to 2031, the cardiovascular diseases segment is expected to achieve the highest CAGR. This growth can be attributed to the increasing prevalence of cardiovascular diseases and the exploration of gene therapies to address genetic cardiovascular disorders.

Clinical Manufacturing dominated Dominates the Market by Application

The market is segmented by application into Clinical Manufacturing and Commercial Manufacturing. In 2022, Clinical Manufacturing dominated the market due to the emphasis on research and development activities. However, from 2023 to 2031, Commercial Manufacturing is projected to exhibit the highest CAGR. This growth is driven by the progression of promising cell and gene therapies from clinical trials to commercialization, as therapies gain regulatory approvals and enter the market.

North America Remains as the Global Leader

In terms of geographic trends, North America held the highest revenue share in 2022, driven by a robust biotechnology industry, a supportive regulatory environment, and significant investments in research and development. However, the Asia-Pacific region is expected to exhibit the highest CAGR during the forecast period. This growth can be attributed to increasing healthcare infrastructure, rising prevalence of chronic diseases, and growing investments in regenerative medicine and biotechnology.

Market Competition to Intensify during the Forecast Period

Prominent players in the cell and gene therapy manufacturing market include Novartis AG, Kite Pharma , Spark Therapeutics , Bluebird Bio, CRISPR Therapeutics, Lonza, Catalent Inc., F. Hoffmann-La Roche Ltd., Samsung Biologics, Boehringer Ingelheim, Cellular Therapeutics, Hitachi Chemical Co., Ltd., Takara Bio Inc., Miltenyi Biotec, Thermo Fisher Scientific, Merck KGaA, and Wuxi Advanced Therapies. These companies are at the forefront of developing innovative cell and gene therapies, particularly in the oncology and genetic disorders segments. Their key strategies involve partnerships with research institutions, academia, and regulatory agencies to advance clinical trials and accelerate product development. As of 2022, these players have contributed to the growth of the market, with several therapies receiving regulatory approvals. From 2023 to 2031, these companies are expected to continue focusing on expanding their therapy portfolios and enhancing manufacturing capabilities to meet the increasing demand for advanced therapies.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other Key Market Insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cell and Gene Therapy Manufacturing market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Cell and Gene Therapy Manufacturing market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

  • Cell Therapy
    • Allogeneic
    • Mesenchymal Stem Cells
    • T-cells
    • Induced Pluripotent Stem Cells
    • Natural Killer Cells
    • Hematopoietic Stem Cells
    • Other Allogeneic Cells
  • Autologous
    • T-cells
    • Hematopoietic Stem Cells
    • Mesenchymal Stem Cells
    • Natural Killer Cells
    • Other AutologousCells
  • Viral Vector
    • Retroviral Vectors
    • Adeno-associated Virus Vectors
    • Other Viral Vectors
  • Gene Therapy
    • Viral Vector
    • Retroviral Vectors
    • Adeno-associated Virus Vectors
    • Other Viral Vectors
  • Non-viral Vector
    • Oligonucleotides
    • Other Non-viral Vectors

Indication

  • Oncology Diseases
  • Cardiovascular Diseases
  • Orthopedic Diseases
  • Ophthalmology Diseases
  • Central Nervous System Disorders
  • Infectious Diseases
  • Other Indications

Application

  • Clinical Manufacturing
  • Commercial Manufacturing

End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Other End Users

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Cell and Gene Therapy Manufacturing market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Cell and Gene Therapy Manufacturing market?
  • Which is the largest regional market for Cell and Gene Therapy Manufacturing market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Cell and Gene Therapy Manufacturing market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Cell and Gene Therapy Manufacturing market worldwide?
Show more
Product Code: 139807-09-23

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Cell and Gene Therapy Manufacturing Market
  • 2.2. Global Cell and Gene Therapy Manufacturing Market, By Type, 2022 (US$ Million)
  • 2.3. Global Cell and Gene Therapy Manufacturing Market, By Indication, 2022 (US$ Million)
  • 2.4. Global Cell and Gene Therapy Manufacturing Market, By Application, 2022 (US$ Million)
  • 2.5. Global Cell and Gene Therapy Manufacturing Market, By End User, 2022 (US$ Million)
  • 2.6. Global Cell and Gene Therapy Manufacturing Market, By Geography, 2022 (US$ Million)
  • 2.7. Attractive Investment Proposition by Geography, 2022

3. Cell and Gene Therapy Manufacturing Market: Competitive Analysis

  • 3.1. Market Positioning of Key Cell and Gene Therapy Manufacturing Market Vendors
  • 3.2. Strategies Adopted by Cell and Gene Therapy Manufacturing Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Cell and Gene Therapy Manufacturing Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Cell and Gene Therapy Manufacturing Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Cell Therapy
      • 5.3.1.1. Allogeneic
        • 5.3.1.1.1. Mesenchymal Stem Cells
        • 5.3.1.1.2. T-cells
        • 5.3.1.1.3. Induced Pluripotent Stem Cells
        • 5.3.1.1.4. Natural Killer Cells
        • 5.3.1.1.5. Hematopoietic Stem Cells
        • 5.3.1.1.6. Other Allogeneic Cells
      • 5.3.1.2. Autologous
        • 5.3.1.2.1. T-cells
        • 5.3.1.2.2. Hematopoietic Stem Cells
        • 5.3.1.2.3. Mesenchymal Stem Cells
        • 5.3.1.2.4. Natural Killer Cells
        • 5.3.1.2.5. Other AutologousCells
      • 5.3.1.3. Viral Vector
        • 5.3.1.3.1. Retroviral Vectors
        • 5.3.1.3.2. Adeno-associated Virus Vectors
        • 5.3.1.3.3. Other Viral Vectors
    • 5.3.2. Gene Therapy
      • 5.3.2.1. Viral Vector
        • 5.3.2.1.1. Retroviral Vectors
        • 5.3.2.1.2. Adeno-associated Virus Vectors
        • 5.3.2.1.3. Other Viral Vectors
      • 5.3.2.2. Non-viral Vector
        • 5.3.2.2.1. Oligonucleotides
        • 5.3.2.2.2. Other Non-viral Vectors

6. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Oncology Diseases
    • 6.3.2. Cardiovascular Diseases
    • 6.3.3. Orthopedic Diseases
    • 6.3.4. Ophthalmology Diseases
    • 6.3.5. Central Nervous System Disorders
    • 6.3.6. Infectious Diseases
    • 6.3.7. Other Indications

7. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Clinical Manufacturing
    • 7.3.2. Commercial Manufacturing

8. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 8.3. Market Segmentation
    • 8.3.1. Pharmaceutical & Biotechnology Companies
    • 8.3.2. Academic & Research Institutes
    • 8.3.3. Other End Users

9. North America Cell and Gene Therapy Manufacturing Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
  • 9.3. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
  • 9.4. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 9.5. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
  • 9.6.Cell and Gene Therapy Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 9.6.1.North America
      • 9.6.1.1. U.S.
        • 9.6.1.1.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 9.6.1.1.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 9.6.1.1.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 9.6.1.1.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 9.6.1.2. Canada
        • 9.6.1.2.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 9.6.1.2.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 9.6.1.2.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 9.6.1.2.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 9.6.1.3. Rest of North America
        • 9.6.1.3.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 9.6.1.3.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 9.6.1.3.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 9.6.1.3.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)

10. UK and European Union Cell and Gene Therapy Manufacturing Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
  • 10.3. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
  • 10.4. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 10.5. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
  • 10.6.Cell and Gene Therapy Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 10.6.1.UK and European Union
      • 10.6.1.1. UK
        • 10.6.1.1.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 10.6.1.1.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 10.6.1.1.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.6.1.1.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 10.6.1.2. Germany
        • 10.6.1.2.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 10.6.1.2.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 10.6.1.2.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.6.1.2.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 10.6.1.3. Spain
        • 10.6.1.3.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 10.6.1.3.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 10.6.1.3.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.6.1.3.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 10.6.1.4. Italy
        • 10.6.1.4.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 10.6.1.4.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 10.6.1.4.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.6.1.4.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 10.6.1.5. France
        • 10.6.1.5.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 10.6.1.5.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 10.6.1.5.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.6.1.5.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 10.6.1.6. Rest of Europe
        • 10.6.1.6.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 10.6.1.6.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 10.6.1.6.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 10.6.1.6.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)

11. Asia Pacific Cell and Gene Therapy Manufacturing Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
  • 11.3. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
  • 11.4. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 11.5. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
  • 11.6.Cell and Gene Therapy Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 11.6.1.Asia Pacific
      • 11.6.1.1. China
        • 11.6.1.1.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 11.6.1.1.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 11.6.1.1.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.6.1.1.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 11.6.1.2. Japan
        • 11.6.1.2.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 11.6.1.2.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 11.6.1.2.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.6.1.2.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 11.6.1.3. India
        • 11.6.1.3.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 11.6.1.3.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 11.6.1.3.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.6.1.3.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 11.6.1.4. Australia
        • 11.6.1.4.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 11.6.1.4.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 11.6.1.4.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.6.1.4.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 11.6.1.5. South Korea
        • 11.6.1.5.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 11.6.1.5.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 11.6.1.5.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.6.1.5.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 11.6.1.6. Rest of Asia Pacific
        • 11.6.1.6.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 11.6.1.6.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 11.6.1.6.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 11.6.1.6.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)

12. Latin America Cell and Gene Therapy Manufacturing Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
  • 12.3. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
  • 12.4. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 12.5. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
  • 12.6.Cell and Gene Therapy Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 12.6.1.Latin America
      • 12.6.1.1. Brazil
        • 12.6.1.1.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 12.6.1.1.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 12.6.1.1.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.6.1.1.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 12.6.1.2. Mexico
        • 12.6.1.2.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 12.6.1.2.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 12.6.1.2.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.6.1.2.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 12.6.1.3. Rest of Latin America
        • 12.6.1.3.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 12.6.1.3.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 12.6.1.3.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 12.6.1.3.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)

13. Middle East and Africa Cell and Gene Therapy Manufacturing Market, 2021-2031, USD (Million)

  • 13.1. Market Overview
  • 13.2. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
  • 13.3. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
  • 13.4. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 13.5. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
  • 13.6.Cell and Gene Therapy Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 13.6.1.Middle East and Africa
      • 13.6.1.1. GCC
        • 13.6.1.1.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 13.6.1.1.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 13.6.1.1.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 13.6.1.1.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 13.6.1.2. Africa
        • 13.6.1.2.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 13.6.1.2.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 13.6.1.2.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 13.6.1.2.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)
      • 13.6.1.3. Rest of Middle East and Africa
        • 13.6.1.3.1. Cell and Gene Therapy Manufacturing Market: By Type, 2021-2031, USD (Million)
        • 13.6.1.3.2. Cell and Gene Therapy Manufacturing Market: By Indication, 2021-2031, USD (Million)
        • 13.6.1.3.3. Cell and Gene Therapy Manufacturing Market: By Application, 2021-2031, USD (Million)
        • 13.6.1.3.4. Cell and Gene Therapy Manufacturing Market: By End User, 2021-2031, USD (Million)

14. Company Profile

  • 14.1. Novartis AG
    • 14.1.1. Company Overview
    • 14.1.2. Financial Performance
    • 14.1.3. Product Portfolio
    • 14.1.4. Strategic Initiatives
  • 14.2. Kite Pharma
    • 14.2.1. Company Overview
    • 14.2.2. Financial Performance
    • 14.2.3. Product Portfolio
    • 14.2.4. Strategic Initiatives
  • 14.3. Spark Therapeutics
    • 14.3.1. Company Overview
    • 14.3.2. Financial Performance
    • 14.3.3. Product Portfolio
    • 14.3.4. Strategic Initiatives
  • 14.4. Bluebird Bio
    • 14.4.1. Company Overview
    • 14.4.2. Financial Performance
    • 14.4.3. Product Portfolio
    • 14.4.4. Strategic Initiatives
  • 14.5. CRISPR Therapeutics
    • 14.5.1. Company Overview
    • 14.5.2. Financial Performance
    • 14.5.3. Product Portfolio
    • 14.5.4. Strategic Initiatives
  • 14.6. Lonza
    • 14.6.1. Company Overview
    • 14.6.2. Financial Performance
    • 14.6.3. Product Portfolio
    • 14.6.4. Strategic Initiatives
  • 14.7. Catalent Inc.
    • 14.7.1. Company Overview
    • 14.7.2. Financial Performance
    • 14.7.3. Product Portfolio
    • 14.7.4. Strategic Initiatives
  • 14.8. F. Hoffmann-La Roche Ltd.
    • 14.8.1. Company Overview
    • 14.8.2. Financial Performance
    • 14.8.3. Product Portfolio
    • 14.8.4. Strategic Initiatives
  • 14.9. Samsung Biologics
    • 14.9.1. Company Overview
    • 14.9.2. Financial Performance
    • 14.9.3. Product Portfolio
    • 14.9.4. Strategic Initiatives
  • 14.10. Boehringer Ingelheim
    • 14.10.1. Company Overview
    • 14.10.2. Financial Performance
    • 14.10.3. Product Portfolio
    • 14.10.4. Strategic Initiatives
  • 14.11. Cellular Therapeutics
    • 14.11.1. Company Overview
    • 14.11.2. Financial Performance
    • 14.11.3. Product Portfolio
    • 14.11.4. Strategic Initiatives
  • 14.12. Hitachi Chemical Co., Ltd.
    • 14.12.1. Company Overview
    • 14.12.2. Financial Performance
    • 14.12.3. Product Portfolio
    • 14.12.4. Strategic Initiatives
  • 14.13. Takara Bio Inc.
    • 14.13.1. Company Overview
    • 14.13.2. Financial Performance
    • 14.13.3. Product Portfolio
    • 14.13.4. Strategic Initiatives
  • 14.14. Miltenyi Biotec
    • 14.14.1. Company Overview
    • 14.14.2. Financial Performance
    • 14.14.3. Product Portfolio
    • 14.14.4. Strategic Initiatives
  • 14.15. Thermo Fisher Scientific
    • 14.15.1. Company Overview
    • 14.15.2. Financial Performance
    • 14.15.3. Product Portfolio
    • 14.15.4. Strategic Initiatives
  • 14.16. Merck KGaA
    • 14.16.1. Company Overview
    • 14.16.2. Financial Performance
    • 14.16.3. Product Portfolio
    • 14.16.4. Strategic Initiatives
  • 14.17. Other Notable Players
    • 14.17.1. Company Overview
    • 14.17.2. Financial Performance
    • 14.17.3. Product Portfolio
    • 14.17.4. Strategic Initiatives
Show more
Product Code: 139807-09-23

List of Tables

  • TABLE 1 Global Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 2 Global Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 3 Global Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 4 Global Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 5 Global Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 6 Global Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 7 Global Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 8 Global Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 9 Global Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 10 Global Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 11 Global Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 12 North America Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 13 North America Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 14 North America Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 15 North America Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 16 North America Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 17 North America Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 18 North America Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 19 North America Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 20 North America Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 21 North America Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 22 North America Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 23 U.S. Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 24 U.S. Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 25 U.S. Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 26 U.S. Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 27 U.S. Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 28 U.S. Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 29 U.S. Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 30 U.S. Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 31 U.S. Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 32 U.S. Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 33 U.S. Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 34 Canada Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 35 Canada Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 36 Canada Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 37 Canada Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 38 Canada Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 39 Canada Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 40 Canada Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 41 Canada Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 42 Canada Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 43 Canada Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 44 Canada Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 45 Rest of North America Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 46 Rest of North America Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 47 Rest of North America Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 48 Rest of North America Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 49 Rest of North America Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 50 Rest of North America Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 51 Rest of North America Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 52 Rest of North America Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 53 Rest of North America Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 54 Rest of North America Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 55 Rest of North America Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 56 UK and European Union Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 57 UK and European Union Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 58 UK and European Union Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 59 UK and European Union Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 60 UK and European Union Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 61 UK and European Union Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 62 UK and European Union Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 63 UK and European Union Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 64 UK and European Union Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 65 UK and European Union Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 66 UK and European Union Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 67 UK Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 68 UK Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 69 UK Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 70 UK Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 71 UK Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 72 UK Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 73 UK Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 74 UK Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 75 UK Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 76 UK Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 77 UK Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 78 Germany Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 79 Germany Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 80 Germany Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 81 Germany Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 82 Germany Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 83 Germany Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 84 Germany Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 85 Germany Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 86 Germany Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 87 Germany Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 88 Germany Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 89 Spain Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 90 Spain Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 91 Spain Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 92 Spain Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 93 Spain Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 94 Spain Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 95 Spain Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 96 Spain Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 97 Spain Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 98 Spain Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 99 Spain Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 100 Italy Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 101 Italy Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 102 Italy Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 103 Italy Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 104 Italy Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 105 Italy Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 106 Italy Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 107 Italy Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 108 Italy Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 109 Italy Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 110 Italy Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 111 France Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 112 France Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 113 France Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 114 France Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 115 France Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 116 France Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 117 France Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 118 France Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 119 France Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 120 France Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 121 France Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 122 Rest of Europe Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 123 Rest of Europe Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 124 Rest of Europe Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 125 Rest of Europe Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 126 Rest of Europe Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 127 Rest of Europe Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 128 Rest of Europe Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 129 Rest of Europe Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 130 Rest of Europe Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 131 Rest of Europe Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 132 Rest of Europe Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 133 Asia Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 134 Asia Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 135 Asia Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 136 Asia Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 137 Asia Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 138 Asia Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 139 Asia Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 140 Asia Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 141 Asia Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 142 Asia Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 143 Asia Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 144 China Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 145 China Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 146 China Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 147 China Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 148 China Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 149 China Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 150 China Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 151 China Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 152 China Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 153 China Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 154 China Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 155 Japan Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 156 Japan Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 157 Japan Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 158 Japan Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 159 Japan Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 160 Japan Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 161 Japan Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 162 Japan Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 163 Japan Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 164 Japan Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 165 Japan Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 166 India Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 167 India Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 168 India Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 169 India Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 170 India Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 171 India Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 172 India Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 173 India Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 174 India Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 175 India Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 176 India Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 177 Australia Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 178 Australia Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 179 Australia Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 180 Australia Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 181 Australia Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 182 Australia Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 183 Australia Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 184 Australia Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 185 Australia Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 186 Australia Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 187 Australia Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 188 South Korea Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 189 South Korea Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 190 South Korea Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 191 South Korea Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 192 South Korea Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 193 South Korea Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 194 South Korea Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 195 South Korea Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 196 South Korea Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 197 South Korea Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 198 South Korea Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 199 Latin America Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 200 Latin America Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 201 Latin America Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 202 Latin America Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 203 Latin America Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 204 Latin America Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 205 Latin America Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 206 Latin America Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 207 Latin America Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 208 Latin America Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 209 Latin America Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 210 Brazil Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 211 Brazil Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 212 Brazil Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 213 Brazil Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 214 Brazil Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 215 Brazil Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 216 Brazil Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 217 Brazil Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 218 Brazil Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 219 Brazil Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 220 Brazil Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 221 Mexico Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 222 Mexico Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 223 Mexico Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 224 Mexico Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 225 Mexico Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 226 Mexico Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 227 Mexico Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 228 Mexico Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 229 Mexico Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 230 Mexico Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 231 Mexico Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 232 Rest of Latin America Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 233 Rest of Latin America Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 234 Rest of Latin America Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 235 Rest of Latin America Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 236 Rest of Latin America Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 237 Rest of Latin America Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 238 Rest of Latin America Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 239 Rest of Latin America Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 240 Rest of Latin America Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 241 Rest of Latin America Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 242 Rest of Latin America Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 243 Middle East and Africa Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 244 Middle East and Africa Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 245 Middle East and Africa Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 246 Middle East and Africa Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 247 Middle East and Africa Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 248 Middle East and Africa Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 249 Middle East and Africa Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 250 Middle East and Africa Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 251 Middle East and Africa Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 252 Middle East and Africa Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 253 Middle East and Africa Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 254 GCC Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 255 GCC Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 256 GCC Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 257 GCC Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 258 GCC Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 259 GCC Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 260 GCC Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 261 GCC Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 262 GCC Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 263 GCC Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 264 GCC Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 265 Africa Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 266 Africa Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 267 Africa Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 268 Africa Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 269 Africa Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 270 Africa Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 271 Africa Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 272 Africa Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 273 Africa Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 274 Africa Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 275 Africa Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)
  • TABLE 276 Rest of Middle East and Africa Cell and Gene Therapy Manufacturing Market By Type, 2021-2031, USD (Million)
  • TABLE 277 Rest of Middle East and Africa Cell and Gene Therapy Manufacturing Market By Cell Therapy, 2021-2031, USD (Million)
  • TABLE 278 Rest of Middle East and Africa Cell and Gene Therapy Manufacturing Market By Allogeneic, 2021-2031, USD (Million)
  • TABLE 279 Rest of Middle East and Africa Cell and Gene Therapy Manufacturing Market By Autologous, 2021-2031, USD (Million)
  • TABLE 280 Rest of Middle East and Africa Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 281 Rest of Middle East and Africa Cell and Gene Therapy Manufacturing Market By Gene Therapy, 2021-2031, USD (Million)
  • TABLE 282 Rest of Middle East and Africa Cell and Gene Therapy Manufacturing Market By Viral Vector, 2021-2031, USD (Million)
  • TABLE 283 Rest of Middle East and Africa Cell and Gene Therapy Manufacturing Market By Non-viral Vector, 2021-2031, USD (Million)
  • TABLE 284 Rest of Middle East and Africa Cell and Gene Therapy Manufacturing Market By Indication, 2021-2031, USD (Million)
  • TABLE 285 Rest of Middle East and Africa Cell and Gene Therapy Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 286 Rest of Middle East and Africa Cell and Gene Therapy Manufacturing Market By End User, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Cell and Gene Therapy Manufacturing Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Cell and Gene Therapy Manufacturing Market: Quality Assurance
  • FIG. 5 Global Cell and Gene Therapy Manufacturing Market, By Type, 2022
  • FIG. 6 Global Cell and Gene Therapy Manufacturing Market, By Indication, 2022
  • FIG. 7 Global Cell and Gene Therapy Manufacturing Market, By Application, 2022
  • FIG. 8 Global Cell and Gene Therapy Manufacturing Market, By End User, 2022
  • FIG. 9 Global Cell and Gene Therapy Manufacturing Market, By Geography, 2022
  • FIG. 10 Market Geographical Opportunity Matrix - Global Cell and Gene Therapy Manufacturing Market, 2022
  • FIG. 11 Market Positioning of Key Cell and Gene Therapy Manufacturing Market Players, 2022
  • FIG. 12 Global Cell and Gene Therapy Manufacturing Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
  • FIG. 13 Global Cell and Gene Therapy Manufacturing Market, By Type, 2022 Vs 2031, %
  • FIG. 14 Global Cell and Gene Therapy Manufacturing Market, By Indication, 2022 Vs 2031, %
  • FIG. 15 Global Cell and Gene Therapy Manufacturing Market, By Application, 2022 Vs 2031, %
  • FIG. 16 Global Cell and Gene Therapy Manufacturing Market, By End User, 2022 Vs 2031, %
  • FIG. 17 U.S. Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 18 Canada Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 19 Rest of North America Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 20 UK Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 21 Germany Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 22 Spain Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 23 Italy Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 24 France Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 25 Rest of Europe Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 26 China Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 27 Japan Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 28 India Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 29 Australia Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 30 South Korea Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 31 Rest of Asia Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 32 Brazil Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 33 Mexico Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 34 Rest of Latin America Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 35 GCC Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 36 Africa Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 37 Rest of Middle East and Africa Cell and Gene Therapy Manufacturing Market (US$ Million), 2021 - 2031
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!